Publications

• A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
  Haematologica Volume: 108 Page(s): 705 - 716
  03/01/2023 Authors: Pratz KW; Kaplan J; Levy M; Bixby D; Burke PW; Erba H; Wise-Draper TM; Roboz GJ; Papadantonakis N; Rajkhowa T
• Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.
  Lab Med Volume: 54 Page(s): 13 - 22
  01/05/2023 Authors: Puglianini OC; Peker D; Zhang L; Papadantonakis N
• AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.
  Sci Rep Volume: 12 Page(s): 5809
  04/06/2022 Authors: Reddi D; Seaton BW; Woolston D; Aicher L; Monroe LD; Mao ZJ; Harrell JC; Radich JP; Advani A; Papadantonakis N
• Acute Myeloid Leukemia Case Harboring Unusual FLT3 Variant: Somatic vs Germline?
  Lab Med Volume: 52 Page(s): e53 - e56
  05/04/2021 Authors: Singh N; Morlote D; Vnencak-Jones C; Papadantonakis N; Harada S
• Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
  Hematol Oncol Stem Cell Ther Volume: 13 Page(s): 143 - 146
  09/01/2020 Authors: Shah G; Mikhail FM; Bachiasvili K; Vachhani P; Erba HP; Papadantonakis N
• Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
  Volume: 20 Page(s): S325 - S325
  09/01/2020 Authors: Harrison C; Garcia JS; Mesa R; Somervaille T; Ritchie EK; Komrokji RS; Pemmaraju N; Jamieson C; Papadantonakis N; Foran JM
• Integrating touchscreen-based geriatric assessment and frailty screening for adults with acute myelogenous leukemia to drive personalized treatment decisions.
  Volume: 38
  05/20/2020 Authors: Wujcik D; Papadantonakis N; Wall SA; Kasner MT; Jamy OH; Dudley W; Ingram SA; Lawhon V; Son U; Dudley M
• Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.
  Ther Adv Hematol Volume: 11 Page(s): 2040620720929475
  01/01/2020 Authors: Castaneda Puglianini O; Papadantonakis N
• Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results.
  Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 31 - 38
  01/01/2020 Authors: Jamy O; Bodine C; Sampat D; Sarmad R; Chadha A; Vachhani P; Papadantonakis N; Di Stasi A
• FLAG and Etoposide as Salvage Treatment in Acute Myeloid Leukemia.
  Acta Haematol Volume: 143 Page(s): 403 - 404
  01/01/2020 Authors: Papadantonakis N
• Ramp-up Treatment Strategy in Philadelphia Positive Acute Lymphoblastic Leukemia Is Associated with Deep Molecular Remissions and Favorable Outcomes
  Volume: 134
  11/13/2019 Authors: Mir NA; Bodine C; Peker D; Bachiashvili K; Vachhani P; Costa LJ; Erba HP; Papadantonakis N
• Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.
  J Natl Compr Canc Netw Volume: 17 Page(s): 414 - 423
  05/01/2019 Authors: Brown PA; Wieduwilt M; Logan A; DeAngelo DJ; Wang ES; Fathi A; Cassaday RD; Litzow M; Advani A; Aoun P
• Chronic myelomonocytic leukemia associated with myeloid sarcomas and NPM1 mutation: a case report and literature review.
  Ther Adv Hematol Volume: 10 Page(s): 2040620719854596
  01/01/2019 Authors: Matanes F; AbdelAzeem BMA; Shah G; Reddy V; Saad A; Papadantonakis N
• Central Nervous System Double Relapse of Acute Promyelocytic Leukemia and Acute Myelomonocytic Leukemia.
  Case Rep Hematol Volume: 2019 Page(s): 4907352
  01/01/2019 Authors: Stanko LM; Reddy V; Mikhail FM; Papadantonakis N
• Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia.
  Case Rep Hematol Volume: 2019 Page(s): 3536517
  01/01/2019 Authors: Shah G; Mikhail FM; Carroll AJ; Kutny M; Papadantonakis N
• Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
  J Natl Compr Canc Netw Volume: 16 Page(s): 1500 - 1537
  12/01/2018 Authors: Gotlib J; Gerds AT; Bose P; Castells MC; Deininger MW; Gojo I; Gundabolu K; Hobbs G; Jamieson C; McMahon B
• The Impact of Cumulative Dose of Cytarabine Consolidation on Outcomes in Older Patients with Acute Myeloid Leukemia
  Volume: 132
  11/29/2018 Authors: Stanko LM; Costa LJ; Peker D; Erba HP; Papadantonakis N
• Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy
  Volume: 132
  11/29/2018 Authors: Jamy O; Bodine C; Sarmad R; Chadha A; Vachhani P; Costa LJ; Saad A; Papadantonakis N; Erba HP; Di Stasi A
• Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
  Leuk Res Volume: 74 Page(s): 64 - 67
  11/01/2018 Authors: Jamy O; Bae S; Costa LJ; Erba HP; Papadantonakis N
• Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
  Leuk Lymphoma Volume: 59 Page(s): 363 - 371
  02/01/2018 Authors: Saygin C; Papadantonakis N; Cassaday RD; Liedtke M; Fischer K; Dunn T; Patel BJ; Sobecks R; Kalaycio M; Sekeres MA
• Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow
  Volume: 130
  12/07/2017 Authors: Jamy O; Bae S; Costa LJ; Erba HP; Papadantonakis N
• NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
  J Natl Compr Canc Netw Volume: 15 Page(s): 1193 - 1207
  10/01/2017 Authors: Mesa RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G
• Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response
  Volume: 128
  12/02/2016 Authors: Saygin C; Papadantonakis N; Cassaday RD; Liedtke M; Fischer K; Dunn TJ; Patel B; Hobson S; Zimmerman C; Fensterl JL
• Recent advances and novel treatment paradigms in acute lymphocytic leukemia.
  Ther Adv Hematol Volume: 7 Page(s): 252 - 269
  10/01/2016 Authors: Papadantonakis N; Advani AS
• Lysyl oxidase is associated with increased thrombosis and platelet reactivity.
  Blood Volume: 127 Page(s): 1493 - 1501
  03/17/2016 Authors: Matsuura S; Mi R; Koupenova M; Eliades A; Patterson S; Toselli P; Thon J; Italiano JE; Trackman PC; Papadantonakis N
• The Role of Post- Treatment Imaging in Detection of Relapsed Disease in Classical Hodgkin Lymphoma: The Cleveland Clinic Experience
  Volume: 126
  12/03/2015 Authors: Papadantonakis N; Rouphail B; Jia X; Dean RM; Hill BT; Pohlman B; Smith MR; Jagadeesh D
• From the ECM to Thrombosis: a New Role for the Matrix Enzyme Lysyl Oxidase
  Volume: 29
  04/01/2015 Authors: Matsuura S; Mi R; Eliades A; Toselli P; Thon J; Italiano J; Trackman P; Papadantonakis N; Ravid K
• Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
  Future Oncol Volume: 11 Page(s): 1729 - 1739
  01/01/2015 Authors: Bumma N; Papadantonakis N; Advani AS
• Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib
  Volume: 124
  12/06/2014 Authors: Zarzour A; Tabarroki A; Visconte V; Taftaf R; Rogers HJ; Ai J; Papadantonakis N; Lichtin AE; Saunthararajah Y; Stein BL
• Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib
  Volume: 124
  12/06/2014 Authors: Zarzour A; Tabarroki A; Taftaf R; Visconte V; Ai J; Hamilton BK; Papadantonakis N; Lichtin AE; Horwitz LJ; Advani AS
• CD14 and Tissue Factor Positive Extracellular Vesicles Predict Response to Dovitinib in Patients with GBM: A Pilot Study
  Volume: 124
  12/06/2014 Authors: Papadantonakis N; Ahluwalia MS; Khoury M; Chaturvedi S; McCrae KR
• Megakaryocyte polyploidy is inhibited by lysyl oxidase propeptide.
  Cell Cycle Volume: 12 Page(s): 1242 - 1250
  04/15/2013 Authors: Eliades A; Papadantonakis N; Matsuura S; Mi R; Bais MV; Trackman P; Ravid K
• Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection.
  Blood Volume: 120 Page(s): 1774 - 1781
  08/30/2012 Authors: Papadantonakis N; Matsuura S; Ravid K
• Control of myeloproliferative neoplasms by lysyl oxidase
  Volume: 30 Page(s): S7 - S7
  01/01/2012 Authors: Eliades A; Papadantonakis N; Matsuura S; Ravid K
• Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase.
  J Biol Chem Volume: 286 Page(s): 27630 - 27638
  08/05/2011 Authors: Eliades A; Papadantonakis N; Bhupatiraju A; Burridge KA; Johnston-Cox HA; Migliaccio AR; Crispino JD; Lucero HA; Trackman PC; Ravid K
• New roles for cyclin E in megakaryocytic polyploidization.
  J Biol Chem Volume: 285 Page(s): 18909 - 18917
  06/11/2010 Authors: Eliades A; Papadantonakis N; Ravid K
• Direct visualization of the endomitotic cell cycle in living megakaryocytes: differential patterns in low and high ploidy cells.
  Cell Cycle Volume: 7 Page(s): 2352 - 2356
  08/01/2008 Authors: Papadantonakis N; Makitalo M; McCrann DJ; Liu K; Nguyen HG; Martin G; Patel-Hett S; Italiano JE; Ravid K
• Survivin overexpression alone does not alter megakaryocyte ploidy nor interfere with erythroid/megakaryocytic lineage development in transgenic mice.
  Blood Volume: 111 Page(s): 4092 - 4095
  04/15/2008 Authors: McCrann DJ; Yezefski T; Nguyen HG; Papadantonakis N; Liu H; Wen Q; Crispino JD; Ravid K
• Transforming growth factor-beta1 affects interleukin-10 production in the bone marrow of patients with chronic idiopathic neutropenia.
  Eur J Haematol Volume: 79 Page(s): 531 - 538
  12/01/2007 Authors: Pyrovolaki K; Mavroudi I; Papadantonakis N; Velegraki M; Ximeri M; Kalpadakis C; Gvazava G; Klaus M; Eliopoulos GD; Papadaki HA